DiaMedica Therapeutics: Risk-Reward Favors Following Insider Optimism

Stock Information for Athersys Inc.

Loading

Please wait while we load your information from QuoteMedia.

More Recent News About Athersys Inc.

Athersys Reports Third Quarter 2023 Financial Results and Business Highlights
Athersys Extends Near Term Liquidity with Proceeds from Warrant Inducement and Global ARDS License with Healios to Explore Strategic Alternatives
Athersys Reports Interim Analysis Results of MASTERS-2 Clinical Study with MultiStem in Ischemic Stroke, Signs Memorandum of Understanding (MOU) for Global ARDS License with Healios
Athersys Licenses its Animal Health Assets to Ardent Animal Health
Athersys Director Jane Wasman Appointed Board Chair
Grant Awarded to Newcastle University to Research Athersys' MultiStem® in Machine Perfusion Prior to Kidney Transplantation
Athersys, Inc. Announces Pricing of $3.5 Million Public Offering
Athersys Reports Second Quarter 2023 Financial Results and Business Highlights

Market data content copyright © QuoteMedia. Data delayed at least 15 minutes unless otherwise indicated (view Delay Times for all exchanges). Filings and Fundamentals by Morningstar. Insiders by Morningstar (USA) and SEDI (CDN). Analyst ratings by Zacks. Terms of Use.